Scientific output of the emerging Cuban biopharmaceutical industry: a scientometric approach

Ricardo Arencibia-Jorge (), Elena Corera-Alvarez (), Zaida Chinchilla-Rodríguez () and Félix Moya-Anegón ()
Additional contact information
Ricardo Arencibia-Jorge: National Center for Scientific Research (CNIC)
Elena Corera-Alvarez: CCHS-CSIC
Zaida Chinchilla-Rodríguez: CCHS-CSIC
Félix Moya-Anegón: CCHS-CSIC

Scientometrics, 2016, vol. 108, issue 3, No 32, 1636 pages

Abstract: Abstract Cuba has developed a biopharmaceutical sector that involves some of the country’s most relevant scientific institutions. Despite the severe constraints on resources resulting from the U.S. embargo, the results achieved by this sector have contributed to put the country’s health indicators at the same level of high-income nations. Recently, the creation of BioCubaFarma as a cluster of high-technology enterprises organized around a closed cycle model becomes one of the most relevant efforts of the Island in order to make biopharmaceuticals one of the country’s leading export earners. The main aim of the current paper was to characterize BioCubaFarma through a battery of Scopus-based bibliometric indicators. A comparison with the most productive multinational pharmaceutical companies was made. Regression analysis of annual productivity, number of citations, scientific talent pool, innovative knowledge and other citation-based indicators was performed. Differences and similarities between BioCubaFarma and multinational companies in four Scopus subject categories related to this sector were identified. The most productive and visible institutions from BioCubaFarma were also characterized. Qualified human resources, innovative knowledge, leadership, high specialization in the field of vaccines development and non-dependence of international collaboration are strengths of the organization. However, it is still necessary to increase the number of articles published in highly visible journals with the aim to achieve a better citation-based performance. Moreover, to increase the contributions from less-productive institutions, more clinical research published in medical journals and more collaboration with universities and health institutions could also have positive benefits for BioCubaFarma’s pipelines and portfolios.

Keywords: Biopharmaceuticals; Pharmaceutical industry; Scientometrics; Bibliometric indicators; Leadership; Excellence; International collaboration; Multinational companies; Cuba (search for similar items in EconPapers)
Date: 2016
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (8)

Downloads: (external link)
http://link.springer.com/10.1007/s11192-016-2023-1 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:scient:v:108:y:2016:i:3:d:10.1007_s11192-016-2023-1

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/11192

DOI: 10.1007/s11192-016-2023-1

Access Statistics for this article

Scientometrics is currently edited by Wolfgang Glänzel

More articles in Scientometrics from Springer, Akadémiai Kiadó
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().